Alzinova’s Bold Leap: Is the Stock a Calculated Gamble or a Promising Opportunity?
Alzinova’s 2.44% rise and Phase 2a trial launch for ALZ‑101 in early Alzheimer’s spark cautious optimism, but investors must weigh regulatory risks and market volatility.
2 minutes to read